NO128052B - - Google Patents

Download PDF

Info

Publication number: NO128052B
Authority: NO; Norway
Prior art keywords: pamoate; dibenz; monosodium; basic; dimethylamino
Prior art date: 1969-01-29

Application number

NO00025/70A

Other languages

English (en)

Norwegian (no)

Inventor

H Asche

Original Assignee

Ciba Geigy Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1969-01-29

Filing date

1970-01-05

Publication date

1973-09-24

1970-01-05 Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag

1973-09-24 Publication of NO128052B publication Critical patent/NO128052B/no

Links

LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
150000003839 salts Chemical class 0.000 claims description 17
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 11
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims description 11
DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 11
235000013772 propylene glycol Nutrition 0.000 claims description 11
229960004025 sodium salicylate Drugs 0.000 claims description 11
239000002253 acid Substances 0.000 claims description 10
239000000203 mixture Substances 0.000 claims description 9
-1 aliphatic polyols Chemical class 0.000 claims description 8
150000001875 compounds Chemical class 0.000 claims description 8
239000000126 substance Substances 0.000 claims description 8
YGLLICRFEVEWOZ-UHFFFAOYSA-L disodium;3-carboxy-1-[(3-carboxy-2-oxidonaphthalen-1-yl)methyl]naphthalen-2-olate Chemical compound [Na+].[Na+].C1=CC=C2C(CC3=C4C=CC=CC4=CC(=C3O)C([O-])=O)=C(O)C(C([O-])=O)=CC2=C1 YGLLICRFEVEWOZ-UHFFFAOYSA-L 0.000 claims description 6
230000001225 therapeutic effect Effects 0.000 claims description 6
238000011065 in-situ storage Methods 0.000 claims description 5
239000007788 liquid Substances 0.000 claims description 5
229910052757 nitrogen Inorganic materials 0.000 claims description 5
125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
229920005862 polyol Polymers 0.000 claims description 5
239000000654 additive Substances 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
238000000034 method Methods 0.000 claims description 4
GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims description 3
239000003963 antioxidant agent Substances 0.000 claims description 3
150000007514 bases Chemical class 0.000 claims description 3
230000015572 biosynthetic process Effects 0.000 claims description 3
238000004090 dissolution Methods 0.000 claims description 3
125000006413 ring segment Chemical group 0.000 claims description 2
239000013543 active substance Substances 0.000 description 12
239000000243 solution Substances 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
150000007530 organic bases Chemical class 0.000 description 10
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 6
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
239000000600 sorbitol Substances 0.000 description 6
239000012153 distilled water Substances 0.000 description 5
235000011187 glycerol Nutrition 0.000 description 5
YNZFUWZUGRBMHL-UHFFFAOYSA-N 2-[4-[3-(11-benzo[b][1]benzazepinyl)propyl]-1-piperazinyl]ethanol Chemical compound C1CN(CCO)CCN1CCCN1C2=CC=CC=C2C=CC2=CC=CC=C21 YNZFUWZUGRBMHL-UHFFFAOYSA-N 0.000 description 4
PXHIRIWYXDUSMR-UHFFFAOYSA-N ketipramine Chemical compound C1C(=O)C2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 PXHIRIWYXDUSMR-UHFFFAOYSA-N 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
239000003814 drug Substances 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 description 3
150000003840 hydrochlorides Chemical class 0.000 description 3
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 3
XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 3
229960002102 imipramine hydrochloride Drugs 0.000 description 3
229960005290 opipramol Drugs 0.000 description 3
235000010265 sodium sulphite Nutrition 0.000 description 3
FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical class OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
230000000954 anitussive effect Effects 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
229940124584 antitussives Drugs 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
229960004801 imipramine Drugs 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000003589 local anesthetic agent Substances 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000019640 taste Nutrition 0.000 description 2
NZFNXWQNBYZDAQ-UHFFFAOYSA-N thioridazine hydrochloride Chemical compound Cl.C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C NZFNXWQNBYZDAQ-UHFFFAOYSA-N 0.000 description 2
FGBFEFJZYZDLSZ-UHFFFAOYSA-N 5,7-dimethoxy-2,3-dimethyl-2,3-dihydroinden-1-one Chemical compound COC1=CC(OC)=CC2=C1C(=O)C(C)C2C FGBFEFJZYZDLSZ-UHFFFAOYSA-N 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
244000248349 Citrus limon Species 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
229960000836 amitriptyline Drugs 0.000 description 1
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000019658 bitter taste Nutrition 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
229960004606 clomipramine Drugs 0.000 description 1
WIMWMKZEIBHDTH-UHFFFAOYSA-N clomipramine hydrochloride Chemical compound Cl.C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 WIMWMKZEIBHDTH-UHFFFAOYSA-N 0.000 description 1
229960001564 clomipramine hydrochloride Drugs 0.000 description 1
230000007423 decrease Effects 0.000 description 1
229960003914 desipramine Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
229960004903 invert sugar Drugs 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
239000003921 oil Substances 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001294 propane Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
239000013558 reference substance Substances 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
235000020374 simple syrup Nutrition 0.000 description 1
230000002048 spasmolytic effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
239000000725 suspension Substances 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
230000009967 tasteless effect Effects 0.000 description 1
229960002784 thioridazine Drugs 0.000 description 1
229960004098 thioridazine hydrochloride Drugs 0.000 description 1
235000020047 vermouth Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO00025/70A 1969-01-29 1970-01-05 NO128052B (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH133569A CH524372A (de)	1969-01-29	1969-01-29	Verfahren zur Herstellung von stabilen Elixieren, welche therapeutisch verwendbare tricyclische basische Wirkstoffe in Form ihrer Mononatriumpamoate enthalten

Publications (1)

Publication Number	Publication Date
NO128052B true NO128052B (da)	1973-09-24

Family

ID=4208063

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO00025/70A NO128052B (da)	1969-01-29	1970-01-05

Country Status (14)

Country	Link
US (1)	US3733410A (da)
AT (1)	AT293608B (da)
BE (1)	BE744084A (da)
BR (1)	BR7016425D0 (da)
CA (1)	CA920511A (da)
CH (1)	CH524372A (da)
DE (1)	DE2000322C3 (da)
DK (1)	DK129079B (da)
FR (1)	FR2034501A1 (da)
GB (1)	GB1292873A (da)
IE (1)	IE33913B1 (da)
IL (1)	IL33669A (da)
NL (1)	NL7000063A (da)
NO (1)	NO128052B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2213055B2 (da) *	1973-01-08	1976-07-16	Sogeras
DE2631947B2 (de) *	1976-07-15	1980-11-27	Bayer Ag, 5090 Leverkusen	Verwendung von ätherischen ölen und Äthylalkohol
US4684666A (en) *	1986-08-19	1987-08-04	Haas Pharmaceuticals, Inc.	Stabilized liquid analgesic compositions
US4859704A (en) *	1987-10-15	1989-08-22	Oratech Pharmaceutical Development Corporation	Water soluble ibuprofen compositions and methods of making them
US4861797A (en) *	1987-10-15	1989-08-29	Oratech Pharmaceutical Development Corporation	Liquid ibuprofen compositions and methods of making them
DE19633480A1 (de) *	1996-08-20	1998-02-26	Bayer Ag	Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren
US8883863B1 (en)	2008-04-03	2014-11-11	Pisgah Laboratories, Inc.	Safety of psuedoephedrine drug products

1969
- 1969-01-29 CH CH133569A patent/CH524372A/de not_active IP Right Cessation
1970
- 1970-01-05 NL NL7000063A patent/NL7000063A/xx unknown
- 1970-01-05 AT AT6070A patent/AT293608B/de not_active IP Right Cessation
- 1970-01-05 DK DK2070AA patent/DK129079B/da unknown
- 1970-01-05 DE DE2000322A patent/DE2000322C3/de not_active Expired
- 1970-01-05 NO NO00025/70A patent/NO128052B/no unknown
- 1970-01-06 IL IL33669A patent/IL33669A/xx unknown
- 1970-01-06 IE IE11/70A patent/IE33913B1/xx unknown
- 1970-01-06 GB GB530/70A patent/GB1292873A/en not_active Expired
- 1970-01-06 BE BE744084D patent/BE744084A/xx unknown
- 1970-01-06 US US00001059A patent/US3733410A/en not_active Expired - Lifetime
- 1970-01-06 CA CA071493A patent/CA920511A/en not_active Expired
- 1970-01-06 FR FR7000227A patent/FR2034501A1/fr not_active Withdrawn
- 1970-01-29 BR BR216425/70A patent/BR7016425D0/pt unknown

Also Published As

Publication number	Publication date
CA920511A (en)	1973-02-06
DK129079B (da)	1974-08-19
BR7016425D0 (pt)	1973-04-12
AT293608B (de)	1971-10-25
DK129079C (da)	1975-01-20
NL7000063A (da)	1970-07-31
DE2000322B2 (de)	1979-05-23
IL33669A (en)	1975-02-10
IL33669A0 (en)	1970-03-22
FR2034501A1 (da)	1970-12-11
IE33913L (en)	1970-07-29
BE744084A (fr)	1970-07-06
GB1292873A (en)	1972-10-18
CH524372A (de)	1972-06-30
IE33913B1 (en)	1974-12-11
DE2000322C3 (de)	1982-04-15
DE2000322A1 (de)	1970-07-30
US3733410A (en)	1973-05-15

Publication	Publication Date	Title
US8703156B2 (en)	2014-04-22	Liquid formulation for deferiprone with palatable taste
US20030050252A1 (en)	2003-03-13	Process for preparing tannate liquid and semi-solid dosage forms
AT4423U1 (de)	2001-07-25	Zusammensetzung umfassend amoxycillin und clavulansäure
NO128052B (da)	1973-09-24
US10959985B1 (en)	2021-03-30	Pharmaceutical compositions including carvedilol and methods of using the same
KR100417200B1 (ko)	2004-02-05	세트랄린 경구 농축물
US20210322345A1 (en)	2021-10-21	Midodrine hydrochloride oral solution and uses thereof
US20030096868A1 (en)	2003-05-22	Sertraline oral concentrate
CN107714644B (zh)	2021-05-04	口服使用的悬浮液形式的枸橼酸西地那非的药物组合物
US10016428B2 (en)	2018-07-10	Pharmaceutical composition of sildenafil citrate in the form of a suspension for oral use
ES2722673B2 (es)	2021-03-29	Solución acuosa de ranitidina
DK147727B (da)	1984-11-26	Fremgangsmaade til fremstilling af en solubiliseret og stabiliseret oploesning indeholdende 2-chlor-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepin eller et farmaceutisk acceptabelt salt deraf
US4049809A (en)	1977-09-20	Solution of a oxazepine for oral or parenteral administration
ES2684594B1 (es)	2019-05-16	Solución acuosa de ranitidina exenta de etanol
JP5433508B2 (ja)	2014-03-05	ゾルピデム酒石酸塩含有内用液剤
JP4910428B2 (ja)	2012-04-04	内服液剤組成物
EP1001763A1 (en)	2000-05-24	Aqueous compositions comprising ranitidine and lcmt sucrose
CN102573795A (zh)	2012-07-11	液体药物组合物
Ensom et al.	2002	Stability of mycophenolate mofetil in a 1: 1 mixture of ora-sweet and ora-plus
SG190579A1 (en)	2013-06-28	Liquid formulation for deferiprone with palatable taste